2024
DOI: 10.7759/cureus.54262
|View full text |Cite
|
Sign up to set email alerts
|

Acantholytic Dyskeratosis Consistent With Grover's Disease After Letrozole Therapy

Osman Mahboob,
Yusuf Amawi,
Mohammad T Alkaelani
et al.

Abstract: We present a rare case of Grover's disease (GD) associated with letrozole therapy in a 66-year-old female with stage IV breast cancer. GD is a dermatological condition characterized by papulovesicular lesions typically found on the chest and trunk. While GD is linked to chemotherapeutic agents, its association with letrozole is not well documented. The patient presented with a pruritic rash on her neck, right arm, and trunk, initially misdiagnosed as contact dermatitis. Despite treatment with triamcinolone ace… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 10 publications
0
1
0
Order By: Relevance
“…Additionally, systemic diseases or neurovegetative disruptions affecting sweat secretion may influence the disease's course [4]. The role of medications, especially chemotherapeutic agents such as docetaxel, etoposide, and daunorubicin, as well as aromatase inhibitors such as letrozole, and BRAF inhibitors have been implicated as potential triggers in drug-induced cases of Grover's disease [5,6]. Recent evidence suggests a possible link between Grover's disease and systemic infections such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlighting significant public health implications in the context of the coronavirus disease 2019 (COVID-19) pandemic [7].…”
Section: Introductionmentioning
confidence: 99%
“…Additionally, systemic diseases or neurovegetative disruptions affecting sweat secretion may influence the disease's course [4]. The role of medications, especially chemotherapeutic agents such as docetaxel, etoposide, and daunorubicin, as well as aromatase inhibitors such as letrozole, and BRAF inhibitors have been implicated as potential triggers in drug-induced cases of Grover's disease [5,6]. Recent evidence suggests a possible link between Grover's disease and systemic infections such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlighting significant public health implications in the context of the coronavirus disease 2019 (COVID-19) pandemic [7].…”
Section: Introductionmentioning
confidence: 99%